Cystic Fibrosis Drugs Market Size & Share, by Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, CFTR Modulators); Route of Administration (Oral and Injection); Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

Growth Drivers

Rising Cases of Cystic Fibrosis to Increase the Market Growth

As per the statistics reported by the Cystic Fibrosis Foundation Patient Registry, more than 30,000 people are living with cystic fibrosis in the United States, and more than 70,000 in the world. Moreover, around 1,000 new cases of the disorder are diagnosed every year, with higher than 75% of people being diagnosed with cystic fibrosis by the age of 2. The growing cases of this condition are predicted to raise the demand for cystic fibrosis drugs and thereby increase the demand for newer and improved medications in the cystic fibrosis drugs market.

New Drug Approvals for Cystic Fibrosis Treatment to Expand the Market Size

In 2018, the U.S. Food and Drug Administration (FDA) approved SYMDEKO, a combination of tezacaftor and ivacaftor, for the treatment of cystic fibrosis (CF). The drug is in the form of tablets for oral use by patients above the age of 12 years. In addition to this, there are several drugs for cystic fibrosis that are currently in the developmental phase. On the basis of this, the market for cystic fibrosis drugs is anticipated to grow significantly in the next few years.

Challenges

High Cost of Cystic Fibrosis Drugs to Hamper the Market Growth

One of the major restraints of cystic fibrosis drugs is that the cost is high which prevents a large majority of consumers from buying them, especially those belonging to the low and middle income countries. In order to make the drugs accessible to larger parts of the globe, it is essential to make them cost effective in future.